A Phase 1, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of DGX-001 in Healthy Volunteers Followed by a Stress Exposure Resilience Panel
Latest Information Update: 18 Jan 2024
At a glance
- Drugs DGX-001 (Primary)
- Indications Alzheimer's disease; Major depressive disorder; Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Digestome Therapeutics; Viage Therapeutics
- 26 Jul 2023 Results presented in a Viage Therapeutics Media Release.
- 19 Jun 2023 Status changed from recruiting to completed.
- 29 Jul 2022 Planned number of patients changed from 56 to 70.